Course:
NR 503
Institution:
NR 503
NR 503 MIDTERM EXAM LATEST UPDATE 2025/2026 Q&A PDF Download
✅ Instant PDF Download
✅ Verified answer explanations
✅ Refund if not Satisfied
✅ Prepared for 2025/2026 test cycle
Uploaded on: | April 17, 2025 |
Last updated: | May 2, 2025 |
Number of pages: | 10 |
Written in: | 2025/2026 |
Type: | Exam (elaborations) |
Contains: | Questions & Answers |
Tags: | NR 503 MIDTERM EXAM LATEST UPDATE 2025/2026 Q&A PDF Download |
AdelineJean
Exam (Elaborations)
Bundle Deal! Get all 4 docs for just $21.50
Add to Cart
100% satisfaction guarantee
Refund Upon dissatisfaction
Immediately available after purchase
Available in Both online and PDF
| 0 sold
Bundle for NR 503 Midterm and Final Exams 2025/2026 Latest Update PDF Download
Includes 4 Documents
$21.50
NR 503 MIDTERM EXAM REVIEW QUESTIONS WITH ANSWERS 1. The nurse practitioner is reviewing a recent study that utilizes analytic epidemiology by means of a cohort study design. The cohort study design informs the practitioner about which of the following: Outcomes that develop from an exposure 2. A group of providers have implemented population-based intervention and are now assessing the efficacy of the intervention. Which of the following would be an example of a population based outcome? Decreased mortality rate compared to previous year 3. Appraisal of research publications is critical as providers assess for relevance to population health. Which of the following items should be considered during the appraisal process? Select all that apply. Outcome measure, Transparency, Internal Validity 4. What is being compared in a cohort study design? The incidence of a disease between exposed and non-exposed individuals 5. Analytic epidemiology is best described as: Studies that investigate origins and casuals’ factors of health-related events 6. You are part of a research group investigating association between exposure and disease. Which study design is a best fit for this type of study: Case-Control Study 7. The provider is concerned about what appears to be an increase in the mortality rate for their community. Mortality is an example of which of the following: Vital statistic 8. An example of a tertiary prevention measure for chronic obstructive pulmonary disease is: Pulmonary Rehabilitation 9. Which of the following statements best describe efficacy? It is an estimate of the benefit of treatment under ideal conditions It is an estimate of the reduction of disease in treated groups 10. A study is conducted for a pharmaceutical agent that has shown promise for reducing heart disease among women. In order to more fully test the agent, an additional study is done restricting the participants to be randomized to those who have a history of hypertension. Which of the following advantages cannot be claimed by the researchers?